Gelmetix is a UK-based therapeutic biomaterials company with offices in London, Paris, and Manchester. Their bio-inductive gels are designed to treat patients suffering from chronic lower back pain and osteoarthritis. Their lead product is an injectable gel that targets chronic lower back pain caused by the intervertebral disc. It rehydrates and stabilizes the nucleus pulposus of the disc, restoring its load-bearing properties and movement. Gelmetix's patented polymer gel technology has the potential to be adapted and extended for other uses. In December 2020, Gelmetix was named "one of the most promising biotech start-ups in Europe" by EIT Health Catapult.